扶正化瘀胶囊联合拉米夫定治疗乙型肝炎肝硬化疗效观察

李雅萍，王小萍

（陕西核工业二一五医院消化科，陕西 咸阳，712000）

浏览次数：100次 下载次数：307次

摘要：

目的 探讨扶正化瘀胶囊联合拉米夫定治疗乙型肝炎肝硬化的疗效。方法 将2013年2月至2015年12月在我院进行诊治的乙型肝炎肝硬化患者120例按照平行对照的随机原则分为观察组与对照组，各60例。对照组给予拉米夫定治疗，观察组患者给予扶正化瘀胶囊联合拉米夫定治疗，两组患者均治疗3个月，比较两组疗效。结果观察组的治疗总有效率 （96.6%）明显高于对照组（83.3%）（P<0.05）。治疗前两组血清ALT值比较无显著差异（P>0.05）；治疗后两组ALT值均降低，
且观察组显著优于对照组（P<0.05）。两组治疗后的血清HA、CⅣ、PCⅢ和LN值都明显低于治疗前（P<0.05），同时治疗后观察组的血清HA、CⅣ、PCⅢ和LN 值明显低于对照组（P<0.05）。结论 扶正化瘀胶囊联合拉米夫定治疗乙型肝炎肝硬化，能明显改善肝功能，提高治疗效果，有利于患者总体病情的改善。

关键词：扶正化瘀胶囊；拉米夫定；乙型肝炎肝硬化；肝功能

中图分类号：R512.62文献标志码：A文章编号：2096-1413(2016)27-0008-02

Observation on the therapeutic effect of Fuzheng Huayu capsule combined with lamivudine in the treatment of HBV-related cirrhosis
LI Ya-ping, WANG Xiao-ping
(Department of Gastroenterology, No.215 Hospital of Shaanxi Nuclear Industry, Xianyang 712000, China)

ABSTRACT: Objective To investigate the therapeutic effect of fuzheng huayu capsule combined with lamivudine in the treatment of HBV-related cirrhosis. Methods A total of 120 cases of patients with HBV-related cirrhosis diagnosed and treated in our hospital from February 2013 to December 2015 were selected, and equally divided into observation group and control group according to the parallel control principle of random, with 60 cases in each group. The control group accepted lamivudine, and the observation group received fuzheng huayu capsule combined with lamivudine, the treatment cycles were 3 months. Results The total effective rate of the observation group was 96.6%, which was significantly higher than 83.3% of the control group (P<0.05); there was no significant difference between the two groups before treatment in ALT (P>0.05); after treatment, the ALT of the two groups were all decreased, but the observation group was significantly better than that of the control group (P<0.05); the serum levels of HA, CⅣ、PCⅢ and LN in the two groups after treatment were significantly lower than those before treatment (P<0.05), and the serum levels of HA, CⅣ、PCⅢ and LN in the observation group after treatment were significantly lower than those in the control group (P<0.05). Conclusion It is beneficial to improve the liver function of the patients with HBV -related cirrhosis by using fuzheng huayu capsule combined with lamivudine，it can improve the treatment effect, which is conducive to the improvement of the overall condition.
KEYWORDS: fuzheng huayu capsule; lamivudine; HBV-related cirrhosis; liver function

参考文献：
[1] 孙建民.拉米夫定对肺结核合并非活动性HBsAg 携带者化疗过程的影响[J].中国现代药物应用,2015,15(13):128-129.
[2] 邓庆梅,高勇,何皖伟,等.原发性肝癌患者血清HBV标志物和HBV-DNA测定的临床意义[J].实用肝脏病杂志,2012,15(5):414-416.
[3] 马德强,张银华,康健,等.扶正化瘀胶囊抗肝纤维化临床疗效的研究[J].浙江临床医学,2016,1(23):60-61.
[4] 陈晓乾,姜月红.自拟化瘀降脂汤对46例非酒精性脂肪性肝病血清肝酶、血脂水平改善的影响分析[J].中医临床研究,2015,23(8):98-99.
[5] 李修宏,李修荣,杨永耿.拉米夫定联合还原型谷胱甘肽预防乙型 病毒性肝炎合并肺结核患者肝功能损伤的临床研究[J].中国临床药理学杂志,2015,18(9):1806-1808.
[6] 王守兵,刘星,孟召刚.扶正化瘀胶囊联合恩替卡韦分散片治疗乙 型肝炎肝硬化32 例疗效观察[J].肝脏,2016,21(1):77-78.
[7] 厉景南,李朝霞,任琅,等.拉米夫定治疗初治涂阳肺结核合并乙肝 病毒携带者的临床疗效及对T 淋巴细胞的影响[J].中国基层医药,2015,22(2):295-297.
[8] 曾繁钰,蒋冰,谭璐.Pre-S1 抗原与HBV 血清学标志物和HBV-DNA 的相关性及临床意义[J].武汉大学学报:医学版,2014,35(1):85-88.
[9] 白艳红.恩替卡韦对肺结核合并慢性乙型肝炎患者肝功能的影响 [J].中国药业,2015,3(21):57-58.